Alexander G. Stepchenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexander G. Stepchenko has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Elizaveta V. Pankratova
Engelhardt Institute of Molecular Biology, Russian Academy of Science, Moscow 119334, Russia
3 shared publications - Elizaveta V. Pankratova
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia
2 shared publications - Sofia G. Georgieva
Engelhardt institute of molecular biology, Russia
2 shared publications - Elizaveta V. Bulavkina
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov str., 32, 119991 Moscow, Russia
1 shared publication - Sofia G. Georgieva
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia
1 shared publication - Tatiana N. Portseva
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov str., 32, 119991 Moscow, Russia
1 shared publication
Latest Publications
- Open Access
- 12 July 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (7) , 1075
XMU-MP-1, the Hippo Signaling Pathway MST-1 Kinase Inhibitor, Prevents the Development of Drug Resistance to Doxorubicin in Hematological Tumor Cells
Background/Objectives: The search for new drugs which could suppress drug resistance development in tumor cells is extremely important for clinical practice. Inhibitors of cell signaling pathways that control cell proliferation and death can be used in complex therapy of malignant tumors. Methods: Cell cycle assay using flow cytometry, In Vitro Cell Viability Assay Cell chemosensitivity was analyzed by direct cell counting after trypan blue staining using a microscope. Results: In the present work, we have shown that the combined action of doxorubicin and XMU-MP-1, the MST1/2 kinase inhibitor in the Hippo signaling pathway, prevents drug resistance development in Namalwa cells, significantly slows drug resistance development in K562 cells, and restores the sensitivity of resistant K562 cells to doxorubicin. We have shown that compared to monotherapy, the combination of doxorubicin and XMU-MP-1 causes a significant decrease in cell division rate and cell death in hematological tumor cells such as Burkitt’s lymphoma Namalwa and chronic myeloid leukemia (CML) K562 cells. Cell cycle analysis revealed that the combined action of XMU-MP-1 and doxorubicin caused a catastrophic cell cycle disruption and a significant increase in the number of cells undergoing apoptosis containing fragmented DNA. Conclusions: XMU-MP-1 can be potentially used in combination with anthracyclines for the treatment of hematological malignancies and, in particular, drug-resistant cancer types.
- 12 July 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (7) , 1075
Open AccessXMU-MP-1, the Hippo Signaling Pathway MST-1 Kinase Inhibitor, Prevents the Development of Drug Resistance to Doxorubicin in Hematological Tumor Cells
Background/Objectives: The search for new drugs which could suppress drug resistance development in tumor cells is extremely important for clinical practice. Inhibitors of cell signaling pathways that control cell proliferation and death can be used in complex therapy of malignant tumors. Methods: Cell cycle assay using flow cytometry, In Vitro Cell Viability Assay Cell chemosensitivity was analyzed by direct cell counting after trypan blue staining using a microscope. Results: In the present work, we have shown that the combined action of doxorubicin and XMU-MP-1, the MST1/2 kinase inhibitor in the Hippo signaling pathway, prevents drug resistance development in Namalwa cells, significantly slows drug resistance development in K562 cells, and restores the sensitivity of resistant K562 cells to doxorubicin. We have shown that compared to monotherapy, the combination of doxorubicin and XMU-MP-1 causes a significant decrease in cell division rate and cell death in hematological tumor cells such as Burkitt’s lymphoma Namalwa and chronic myeloid leukemia (CML) K562 cells. Cell cycle analysis revealed that the combined action of XMU-MP-1 and doxorubicin caused a catastrophic cell cycle disruption and a significant increase in the number of cells undergoing apoptosis containing fragmented DNA. Conclusions: XMU-MP-1 can be potentially used in combination with anthracyclines for the treatment of hematological malignancies and, in particular, drug-resistant cancer types.
- Open Access
- 11 May 2026
- Published by MDPI AG in Preprints.org
XMU-MP-1, the Hippo Signaling Pathway MST-1 Kinase Inhibitor, Prevents the Development of Drug Resistance to Doxorubicin in Hematological Tumor Cells
Background/Objectives: Search for the new drugs capable of suppressing the development of drug resistance in tumor cells is extremely important for clinical practice. Cell signaling pathway inhibitors that control cell proliferation and death can be used in the complex therapy of malignant tumors. Methods: Cell cycle assay by flow cytometry, In Vitro Cell Viability Assay Cells chemosensitivity was analyzed by direct cell counting after trypan blue staining using microscope. Results: In the present work, we have shown that the combined action of doxorubicin and XMU-MP-1, the inhibitor of the MST1/2 kinase in the Hippo signaling pathway, prevents the development of drug resistance in Namalwa cells and significantly slows it down in K562 cells. and restores the sensitivity of resistant K562 cells to doxorubicin. We have shown that the combined action of doxorubicin and XMU-MP-1, causes a significant decrease in cell division rate and leads to the death of hematological tumor cells the Burkitt's lymphoma Namalwa, and myeloma K562 cells compared to monotherapy. Cell cycle analysis has demonstrated that the combined action of XMU-MP-1 and doxorubicin results in a catastrophic disruption of the cell cycle, and a significant increase in the number of cells undergoing apoptosis containing fragmented DNA. Conclusions: Thus, XMU-MP-1 can potentially be used in combination with anthracy-clines for the treatment of hematological malignancies and, in particular, the drug-resistant forms of cancer.
- 11 May 2026
- Published by MDPI AG in Preprints.org
Open AccessXMU-MP-1, the Hippo Signaling Pathway MST-1 Kinase Inhibitor, Prevents the Development of Drug Resistance to Doxorubicin in Hematological Tumor Cells
Background/Objectives: Search for the new drugs capable of suppressing the development of drug resistance in tumor cells is extremely important for clinical practice. Cell signaling pathway inhibitors that control cell proliferation and death can be used in the complex therapy of malignant tumors. Methods: Cell cycle assay by flow cytometry, In Vitro Cell Viability Assay Cells chemosensitivity was analyzed by direct cell counting after trypan blue staining using microscope. Results: In the present work, we have shown that the combined action of doxorubicin and XMU-MP-1, the inhibitor of the MST1/2 kinase in the Hippo signaling pathway, prevents the development of drug resistance in Namalwa cells and significantly slows it down in K562 cells. and restores the sensitivity of resistant K562 cells to doxorubicin. We have shown that the combined action of doxorubicin and XMU-MP-1, causes a significant decrease in cell division rate and leads to the death of hematological tumor cells the Burkitt's lymphoma Namalwa, and myeloma K562 cells compared to monotherapy. Cell cycle analysis has demonstrated that the combined action of XMU-MP-1 and doxorubicin results in a catastrophic disruption of the cell cycle, and a significant increase in the number of cells undergoing apoptosis containing fragmented DNA. Conclusions: Thus, XMU-MP-1 can potentially be used in combination with anthracy-clines for the treatment of hematological malignancies and, in particular, the drug-resistant forms of cancer.
- Open Access
- 12 June 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 874
XMU-MP-1, Inhibitor of STE20-like MST1/2 Kinases of the Hippo Signaling Pathway, Suppresses the Cell Cycle, Activates Apoptosis and Autophagy, and Induces Death of Hematopoietic Tumor Cells
Background/Objectives: Currently, there is limited knowledge on the molecular mechanisms of the “non-canonical” Hippo signaling pathway in hematopoietic tumor cells. We have shown that targeting the MST1/2 kinases, which are the key molecules in this signaling pathway, may be an effective approach to the treatment of hematologic tumors. Methods: The methods used in this study include cell growth assays, caspase assays, Western blot hybridizations, flow cytometry, and whole-transcriptome analyses. These methods allowed us to better understand the molecular pathways at play. Results: Our results showed that XMU-MP-1, an inhibitor of MST1/2 kinase, specifically reduces the viability of hematopoietic cancer cells but not breast cancer cells. It effectively inhibits the growth of the tumor B- and T-cell lines by blocking cell cycle progression, mainly during the G2/M phase, inducing apoptosis and autophagy. XMU-MP-1 treatment led to increased caspase 3/7 activity and increased levels of the cleaved PARP protein. Levels of the LC3-II protein were also shown to be increased, while the level of p62 decreased. These changes are associated with apoptosis and autophagy, respectively. RNA-seq analysis has demonstrated that XMU-MP-1 suppressed the expression of cell cycle regulators, such as E2F, and cell division cycle genes CDC6,7,20,25,45; cyclins A2,B1,B2, and cyclin-dependent kinases. At the same time, it increased the expression of genes involved in apoptosis, autophagy, and necroptosis. Conclusions: Combinations of growth assays, caspase assays, Western blotting, and RNA-seq have shown that the dramatic reduction in the number of hematopoietic tumor cells after treatment with XMU-MP-1 is due to both cytostatic and cytotoxic effects. The use of MST1/2 kinase inhibitors could be highly promising for complex therapy of hematological tumors.
- 12 June 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 874
Open AccessXMU-MP-1, Inhibitor of STE20-like MST1/2 Kinases of the Hippo Signaling Pathway, Suppresses the Cell Cycle, Activates Apoptosis and Autophagy, and Induces Death of Hematopoietic Tumor Cells
Background/Objectives: Currently, there is limited knowledge on the molecular mechanisms of the “non-canonical” Hippo signaling pathway in hematopoietic tumor cells. We have shown that targeting the MST1/2 kinases, which are the key molecules in this signaling pathway, may be an effective approach to the treatment of hematologic tumors. Methods: The methods used in this study include cell growth assays, caspase assays, Western blot hybridizations, flow cytometry, and whole-transcriptome analyses. These methods allowed us to better understand the molecular pathways at play. Results: Our results showed that XMU-MP-1, an inhibitor of MST1/2 kinase, specifically reduces the viability of hematopoietic cancer cells but not breast cancer cells. It effectively inhibits the growth of the tumor B- and T-cell lines by blocking cell cycle progression, mainly during the G2/M phase, inducing apoptosis and autophagy. XMU-MP-1 treatment led to increased caspase 3/7 activity and increased levels of the cleaved PARP protein. Levels of the LC3-II protein were also shown to be increased, while the level of p62 decreased. These changes are associated with apoptosis and autophagy, respectively. RNA-seq analysis has demonstrated that XMU-MP-1 suppressed the expression of cell cycle regulators, such as E2F, and cell division cycle genes CDC6,7,20,25,45; cyclins A2,B1,B2, and cyclin-dependent kinases. At the same time, it increased the expression of genes involved in apoptosis, autophagy, and necroptosis. Conclusions: Combinations of growth assays, caspase assays, Western blotting, and RNA-seq have shown that the dramatic reduction in the number of hematopoietic tumor cells after treatment with XMU-MP-1 is due to both cytostatic and cytotoxic effects. The use of MST1/2 kinase inhibitors could be highly promising for complex therapy of hematological tumors.
- Open Access
- 8 May 2025
- Published by MDPI AG in Preprints.org
XMU-MP-1, Inhibitor of STE20-like MST1/2 Kinases of the Hippo Signaling Pathway, Suppresses the Cell Cycle, Activates Apoptosis and Autophagy, and Induces Death of Hematopoietic Tumor Cells
Background/Objectives: Currently, there is limited knowledge about the molecular mechanisms of the "non-canonical" Hippo signaling pathway in hematopoietic tumor cells. We have shown that targeting the MST1/2 kinases, which are key molecules in this signaling pathway, may be an effective approach to treating hematologic tumors. Methods: Cell growth assays, caspase assays, Western blot hybridizations, flow cytometry, and whole transcriptome analyses. These methods allowed us to better understand the molecular pathways at play. Results: Our results showed that XMU-MP-1, an inhibitor of MST1/2 kinase, specifically reduces the viability of hematopoietic cancer cells but not epithelial cells. It effectively inhibits the growth of B- and T-cell tumors by blocking cell cycle progression mainly during the G2/M phase, inducing apoptosis and autophagy. Under XMU-MP-1 treatment, caspase 3/7 activity increases and the level of cleaved PARP protein increases. The protein level of LC3-II also increases, while the level of p62 decreases. These changes are associated with apoptosis and autophagy, respectively. RNA-Seq analysis demonstrated that XMU-MP-1 suppresses the expression of cell cycle regulators, such as E2F and cell division cycle genes CDC6,7,20,25,45; cyclins A2,B1,B2; cyclin dependent kinases. At the same time, it increases the expression of genes involved in apoptosis, autophagy, and necroptosis. Additionally, XMU-MP-1 enhances the effects of doxorubicin, making it a potential candidate for combination therapy in cancer treatment. Conclusions: Combinations of growth assays, caspase assays, Western blotting, and RNA-seq have shown that the dramatic reduction in the number of hematopoietic tumor cells after treatment with XMU-MP-1 is due to both cytostatic and cytotoxic effects. The use of MST1/2 kinase inhibitors could be highly promising for complex therapies of hematological tumors.
- 8 May 2025
- Published by MDPI AG in Preprints.org
Open AccessXMU-MP-1, Inhibitor of STE20-like MST1/2 Kinases of the Hippo Signaling Pathway, Suppresses the Cell Cycle, Activates Apoptosis and Autophagy, and Induces Death of Hematopoietic Tumor Cells
Background/Objectives: Currently, there is limited knowledge about the molecular mechanisms of the "non-canonical" Hippo signaling pathway in hematopoietic tumor cells. We have shown that targeting the MST1/2 kinases, which are key molecules in this signaling pathway, may be an effective approach to treating hematologic tumors. Methods: Cell growth assays, caspase assays, Western blot hybridizations, flow cytometry, and whole transcriptome analyses. These methods allowed us to better understand the molecular pathways at play. Results: Our results showed that XMU-MP-1, an inhibitor of MST1/2 kinase, specifically reduces the viability of hematopoietic cancer cells but not epithelial cells. It effectively inhibits the growth of B- and T-cell tumors by blocking cell cycle progression mainly during the G2/M phase, inducing apoptosis and autophagy. Under XMU-MP-1 treatment, caspase 3/7 activity increases and the level of cleaved PARP protein increases. The protein level of LC3-II also increases, while the level of p62 decreases. These changes are associated with apoptosis and autophagy, respectively. RNA-Seq analysis demonstrated that XMU-MP-1 suppresses the expression of cell cycle regulators, such as E2F and cell division cycle genes CDC6,7,20,25,45; cyclins A2,B1,B2; cyclin dependent kinases. At the same time, it increases the expression of genes involved in apoptosis, autophagy, and necroptosis. Additionally, XMU-MP-1 enhances the effects of doxorubicin, making it a potential candidate for combination therapy in cancer treatment. Conclusions: Combinations of growth assays, caspase assays, Western blotting, and RNA-seq have shown that the dramatic reduction in the number of hematopoietic tumor cells after treatment with XMU-MP-1 is due to both cytostatic and cytotoxic effects. The use of MST1/2 kinase inhibitors could be highly promising for complex therapies of hematological tumors.
- Open Access
Suppression of OCT-1 in Metastatic Breast Cancer Cells Reduces Tumor Metastatic Potential, Hypoxia Resistance, and Drug Resistance
OCT-1/POU2F1 is a ubiquitously expressed transcription factor. Its expression starts at the earliest stage of embryonic development. OCT-1 controls genes involved in the regulation of differentiation, proliferation, cell metabolism, and aging. High levels of OCT-1 transcription factor in tumor cells correlate with tumor malignancy and resistance to antitumor therapy. Here, we report that suppression of OCT-1 in breast cancer cells reduces their metastatic potential and drug resistance. OCT-1 knockdown in the MDA-MB231 breast cancer cells leads to a fivefold decrease (p < 0.01) in cell migration rates in the Boyden chamber. A decrease in the transcription levels of human invasion signature (HIS) genes (ARHGDIB, CAPZA2, PHACTR2, CDC42, XRCC5, and CAV1) has been also demonstrated by real-time PCR, with high expression of these genes being a hallmark of actively metastasizing breast cancer cells. Transcriptional activity of ATF6 response elements is significantly reduced in the cell lines with decreased OCT-1 expression, which results in lower levels of adaptive EPR stress response. OCT-1 knockdown more than two times increases the MDA-MB231 cell death rate in hypoxia and significantly increases the doxorubicin or docetaxel-treated MDA-MB231 cell death rate. Our findings indicate that OCT-1 may be an important therapeutic target and its selective inhibition may have significant therapeutic effects and may improve prognosis in breast cancer patients.
Open AccessSuppression of OCT-1 in Metastatic Breast Cancer Cells Reduces Tumor Metastatic Potential, Hypoxia Resistance, and Drug Resistance
OCT-1/POU2F1 is a ubiquitously expressed transcription factor. Its expression starts at the earliest stage of embryonic development. OCT-1 controls genes involved in the regulation of differentiation, proliferation, cell metabolism, and aging. High levels of OCT-1 transcription factor in tumor cells correlate with tumor malignancy and resistance to antitumor therapy. Here, we report that suppression of OCT-1 in breast cancer cells reduces their metastatic potential and drug resistance. OCT-1 knockdown in the MDA-MB231 breast cancer cells leads to a fivefold decrease (p < 0.01) in cell migration rates in the Boyden chamber. A decrease in the transcription levels of human invasion signature (HIS) genes (ARHGDIB, CAPZA2, PHACTR2, CDC42, XRCC5, and CAV1) has been also demonstrated by real-time PCR, with high expression of these genes being a hallmark of actively metastasizing breast cancer cells. Transcriptional activity of ATF6 response elements is significantly reduced in the cell lines with decreased OCT-1 expression, which results in lower levels of adaptive EPR stress response. OCT-1 knockdown more than two times increases the MDA-MB231 cell death rate in hypoxia and significantly increases the doxorubicin or docetaxel-treated MDA-MB231 cell death rate. Our findings indicate that OCT-1 may be an important therapeutic target and its selective inhibition may have significant therapeutic effects and may improve prognosis in breast cancer patients.